ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Saturday, November 16, 2024

10:30AM-12:30PM: Abstract Number: 0021

A Novel Small Molecule Screening Assay Using Normal Human Chondrocytes Toward Osteoarthritis Drug Discovery

Osteoarthritis & Joint Biology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 0085

A Novel, Potent and Selective TLR7/8 Small Molecule Inhibitor Blocks TLR7/8 Pathway in the Presence of HCQ and Demonstrates Robust Preclinical Efficacy in Lupus Models

SLE – Animal Models Poster

10:30AM-12:30PM: Abstract Number: 0536

A Population Modeling and Simulation of the Effect of Obexelimab Exposure on the QTc Interval in Healthy Volunteers and Patients with Rheumatoid Arthritis or IgG4-Related Disease

RA – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0448

A Pregnant Lupus Patient’s Journey: Single-Center Outcomes and Opportunities

Reproductive Issues in Rheumatic Disorders Poster

10:30AM-12:30PM: Abstract Number: 0441

A Qualitative Improvement Project to Incorporate the Mycophenolate Risk Evaluation and Mitigation Strategies in an Academic Lupus Clinic

Reproductive Issues in Rheumatic Disorders Poster

10:30AM-12:30PM: Abstract Number: 0670

A Randomized, Open-Label, Phase III Trial Comparing Efficacy and Safety of Intravenous Cyclophosphamide, Mycophenolate Mofetil, or Tacrolimus as Induction Therapy in Lupus Nephritis

SLE – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0544

A Two-year Comparison of Spinal and Hip Mobility Between Axial Spondyloarthritis and Chronic Back Pain Patients in the SPondyloArthritis Caught Early (SPACE) Cohort

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0694

A Unified Vascular Phenotype Score Identifies Systemic Sclerosis Endotypes and Predicts Prognostic Outcomes: Results from the EUSTAR Database

Systemic Sclerosis & Related Disorders – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0387

Absolute Agreement and Inter-rater Reliability of a Web-based Standardized Scoring Tool for Magnetic Resonance Images from Children with Chronic Nonbacterial Osteomyelitis (CNO) Amongst Radiologists

Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0582

Achievement of Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry

SpA Including PsA – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0587

Achieving Stringent Disease Control Criteria Was Associated with Greater Work Productivity Improvements in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Studies of Bimekizumab

SpA Including PsA – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0498

ACPA Subtypes, RF Isotypes, and the Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease

RA – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0055

Activating STAT3 Mutations in CD8+ T Cells Correlate to Serological Positivity in Rheumatoid Arthritis

RA – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 0069

Activation of Cardiovascular Inflammation and Wnt Signaling in Spondyloarthritis: Insights from the HLA-B27 Transgenic Rat Model

SpA Including PsA – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 0227

Active Hand Inflammation: Differing Clinical and Ultrasound Patterns in Patients with Rheumatoid Arthritis and Psoriatic Arthritis. A Cross-Sectional and Multicenter Study

Imaging of Rheumatic Diseases Poster I: Inflammatory Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].